Artwork

Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Treatment Intensification in Metastatic HSPC (Republished)

41:26
 
Share
 

Manage episode 461215771 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
  continue reading

385 episodes

Artwork
iconShare
 
Manage episode 461215771 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
  continue reading

385 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play